# To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC

> **NCT03130829** · NA · WITHDRAWN · sponsor: **Hi-Q Marine Biotech International, Ltd.**

## Conditions studied

- NSCLC Stage IV
- NSCLC, Stage III

## Interventions

- **DIETARY_SUPPLEMENT:** Oligo Fucoidan
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT03130829
- **Lead sponsor:** Hi-Q Marine Biotech International, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-04-26
- **Primary completion:** 2020-02-28
- **Final completion:** 2020-04-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** target population is insufficient
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03130829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03130829, "To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03130829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*